多西他赛联合奈达铂治疗一线化疗失败的非小细胞肺癌的临床研究

目的观察多西他赛联合奈达铂二线治疗晚期非小细胞肺癌（NSCLC）的临床疗效及毒副反应,并进行安全评估。方法 65例一线治疗失败的晚期NSCLC患者采用多西他赛＋奈达铂化疗4周期后,用世界卫生组织（WHO）的疗效及抗肿瘤药物急性及亚急性毒性反应分度评价疗效和毒性。结果 65例患者均完成4周期以上化疗,完全缓解（CR）5例,部分缓解（PR）16例,总有效率32.0%,临床症状明显改善,常见的毒性反应有骨髓抑制、胃肠道症状和脱发。结论多西他赛联合奈达铂治疗一线化疗失败的NSCLC疗效确切,可以提高生活质量,毒副反应较轻,耐受性好,值得临床进一步推广研究。

Clinical study of docetaxel and nedaplatin in treatment for patients with non-small-cell lung cancer who have failed First-line chemotherapy

Objective To observe the efficacy and toxicity of docetaxel plus nedaplatin as the second line therapy for with advanced non-small cell lung cancer(NSCLC),and to assess security.Methods Sixty-five NSCLC patients who had failed in first-line chemotherapy received docetaxel and nedaplatin chemotherapy,totally four cycles.The respond and toxicity were evaluated using World Health Organization toxicity scale.Results Among 65 patients,5 patients received complete respond(CR) and 16 patients had partial respond(P...